LRRK2 anticorps (AA 930-961)

N° du produit ABIN3031610

Détail du produit anti-LRRK2 anticorps

Antigène: LRRK2 (Leucine-Rich Repeat Kinase 2 (LRRK2))

Épitope: AA 930-961

Reactivité: Humain, Souris

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp LRRK2 est non-conjugé

Application: Western Blotting (WB), ELISA, Immunofluorescence (IF)

Purification: Antigen affinity purified

Immunogène: A portion of amino acids 930-961 from the human protein was used as the immunogen for this PARK8 antibody.

Isotype: Ig Fraction

Information d'application

Indications d'application: Titration of the PARK8 antibody may be required due to differences in protocols and secondary/substrate sensitivity.\. Western blot: 1:1000,Immunofluorescence: 1:10-1:50

Restrictions: For Research Use only

Stockage

Format: Liquid

Buffer: In 1X PBS, pH 7.4, with 0.09 % sodium azide

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: -20 °C

Stockage commentaire: Aliquot the PARK8 antibody and store frozen at -20°C or colder. Avoid repeated freeze-thaw cycles.

Détails sur LRRK2

Antigène: LRRK2 (Leucine-Rich Repeat Kinase 2 (LRRK2))

Autre désignation: PARK8 (LRRK2 Produits)

Synonymes: anticorps LRRK2, anticorps AURA17, anticorps DARDARIN, anticorps PARK8, anticorps RIPK7, anticorps ROCO2, anticorps 4921513O20Rik, anticorps 9330188B09Rik, anticorps AW561911, anticorps D630001M17Rik, anticorps Gm927, anticorps cI-46, anticorps leucine-rich repeat kinase 2, anticorps leucine rich repeat kinase 2, anticorps lrrk2, anticorps LRRK2, anticorps Lrrk2

Sujet: Parkinson is the second most common neurodegenerative disease after Alzheimers. About 1 percent of people over the age of 65 and 3 percent of people over the age of 75 are affected by the disease. The mutation is the most common cause of Parkinson's disease identified to date. LRRK2/PARK8, a genetic mutation, was recently found linked to about 5 percent of inherited cases of Parkinson's disease. By high-resolution recombination mapping and candidate gene sequencing in 46 families, 6 disease-segregating mutations (5 missense and 1 putative splice site mutation). It may be central to the pathogenesis of several major neurodegenerative disorders associated with parkinsonism. PARK8 belongs to the ROCO protein family and includes a protein kinase domain of the MAPKKK class and several other major functional domains.

UniProt: Q5S007

Pathways: Regulation of G-Protein Coupled Receptor Protein Signaling, Skeletal Muscle Fiber Development